

Subject **Gavi 6.0 Measurement Framework Targets**

Agenda item **14**

Category **For Decision**

Executive Summary

The 2026-2030 strategic period entails operationalisation of Gavi’s most significant reforms and the Gavi 6.0 Measurement, Evaluation and Learning (MEL) approach is designed to systematically integrate the planning, implementation and use of MEL activities to ensure that key decisions are evidence-based, and to provide timely and flexible learning alongside implementation to course correct and adapt more quickly and at scale. This paper provides updates on key elements of the Gavi 6.0 MEL approach, including proposed topline targets for the Gavi 6.0 strategy, evidence prioritisation process, and evaluation workplan and function reform.

Building on prior guidance provided by the Programme and Policy Committee (PPC) and the Board’s approval of the proposed Gavi 6.0 mission and strategy performance indicators at its meeting in July 2025, this paper proposes targets for these indicators for Board decision in July 2026. An Alliance Technical Working Group (TWG) comprised of representatives from Alliance constituencies advised on target development. The proposed targets include relevant commitments made in the Gavi 6.0 Investment Opportunity and an ambition consistent with a reduction the number of zero-dose children by 10% during Gavi 6.0. **The proposed targets were recommended for approval by the PPC in May 2026, subject to final alignment on targets for zero-dose children and inactivated poliovirus vaccine with the TWG.**

Closeout of Gavi 5.1 studies and evaluation activities is in finalisation and five priority learning areas will be detailed out and prioritised as part of the Gavi 6.0 evidence prioritisation approach. The Gavi 6.0 Evaluation workplan was approved by the Board in December 2025 with two evaluations currently underway (i.e. Big Catchup, Private Sector Innovation). With conclusion of the evaluation function component of the Gavi–Global Fund Task Force on collaboration, the evaluation function reform process for revising the Evaluation Policy for Gavi 6.0 is now underway. Gavi and The Global Fund are sharing learning on recent independent assessments of their evaluation functions and areas of convergence and divergence is provided.

Action Requested of the Board

The Gavi Alliance Programme and Policy Committee (PPC) **recommends** to the Gavi Alliance Board that it:

- a) **Approve** the Gavi 6.0 mission and strategy measurement framework targets, as amended by the PPC and subject to alignment on targets for the indicators

- on zero-dose (M4) and completed series of IPV (SG1b.2) with the Alliance Technical Working Group;
- b) **Note** the update on the evidence prioritisation approach and Evaluation Policy revision process.

Next steps/timeline

The final Gavi 6.0 Measurement Framework will be used to inform the design of donor log frames for the 2026-2030 period and reporting against the Gavi 6.0 Measurement Framework will begin in 2027 when results for 2026 become available. The Gavi Secretariat will finalise the more operationally focused Gavi Leap Master Dashboard, in consultation with Alliance stakeholders, to support initial reporting in the second half of 2026 to guide operational monitoring, learning and early course correction.

The learning questions for identified use cases for priority delivery in 2026-2027 will be detailed with the Evaluation Advisory Committee (EAC), Alliance partners and other stakeholders, prioritised and commissioned and an update will be provided to the PPC in October 2026.

The Secretariat will continue to work with the EAC, PPC and governance bodies through 2026 to ensure that the evaluation reform and revised Evaluation Policy are aligned with broader reforms and to meet the strategic needs of Gavi 6.0.

Previous Board Committee or Board deliberations related to this topic

In May 2026 PPC meeting book: Doc 09 - Gavi 6.0 Measurement Framework targets & Update from the EAC

In December 2025 Board meeting book: Doc 06 - EAC Chair Report to the Board

In October 2025 PPC meeting book: Doc 10 *Update on Measurement, Evaluation and Learning*

In July 2025 Board meeting book: *Consent Agenda Doc 01d, Annex E*

In May 2025 PPC meeting book: Doc 13 *Measurement, Evaluation and Learning for Gavi 6.0*

In December 2024 Board meeting book: Doc 06c *Gavi 6.0 Measurement Framework*

In June 2024 Board meeting book: Doc 06 Annex C *Gavi 6.0 High level approach to operationalising the new strategy*

Report

1. Update on Gavi 6.0 Measurement, Evaluation and Learning approach

- 1.1 In Gavi 6.0, monitoring, evaluation and learning (MEL) activities are systematically designed as an integrated approach within the Execution Framework to enable evidence-based decision-making and implementation at country and portfolio levels alongside roll out of the Gavi Leap reforms. This paper provides updates on key elements of the Gavi 6.0 MEL approach.

2. Setting ambition for the Gavi 6.0 Measurement Framework

- 2.1 The Gavi 6.0 Measurement Framework defines the topline mission and strategy performance indicators and targets to measure the Gavi 6.0 strategy objectives. It defines the “vision of success” for the strategy, with shared Alliance accountability, and will support Board management of the strategy. The targets are based on forecasted expenditure and programming and therefore are intended to be ambitious but achievable. The Board approved the indicators in July 2025 (Annex B). Interpretation will be supported by the Gavi Leap Master Dashboard (Annex C) operational metrics with defined accountabilities for the Secretariat, partners and countries.
- 2.2 An Alliance Technical Working Group (TWG) of monitoring and evaluation specialists, including representatives from countries and Alliance partners with overlap with the Immunisation Agenda 2030 (IA2030) Monitoring and Evaluation Working Group, advised on the Gavi 6.0 Measurement Framework.
- 2.3 The Secretariat confirmed with the TWG that the indicators approved by the Board remain relevant for Gavi 6.0 following recalibration in July 2025. Many indicators aggregate over 56 Gavi eligible countries, which excludes India. It is proposed to use 2025 as the baseline for Gavi 6.0 mission and strategy targets, noting values for many indicators will be available later this year.
- 2.4 Gavi’s financial forecast is a key input to target setting to ensure coherence between anticipated expenditure and programmatic ambition. Proposed targets for Gavi 6.0 were based on the v23 forecast, which was brought to the Audit and Finance Committee in October 2025 and the Board in December 2025, and the v23.1 update which further incorporates Board recalibration decisions.
- 2.5 In Gavi 6.0, for the first time countries have long-term visibility on the resources available to them to allow for greater country ownership on how they invest Gavi funds through a single application. As Gavi targets must take country demand into account, the programmatic forecasting underlying several of the proposed targets is uncertain at this stage. Country ambition will be better understood through their applications for Gavi support, which are expected over 2026-2027.
- 2.6 Country immunisation programmes face significant challenges. As Gavi utilises a contribution approach to results, broad fiscal constraints, a drop in official development assistance (ODA) to 2015 levels, and reduced Gavi support make

it difficult to fully anticipate the implications for projecting future trends. Countries are facing increased fragility and conflict, and the duration of these crises and extent to which they influence ability to deliver results is unclear. To mitigate this risk, the Secretariat will transparently monitor key assumptions underpinning the proposed targets (Annex A) and, should there be important deviations, return to the Board mid-strategy to discuss possible adjustments.

3. Targets for Gavi 6.0 Mission Indicators

3.1 Gavi made commitments against three Gavi 6.0 mission indicators in the Gavi 2026-2030 Investment Opportunity. It is proposed to use those commitments as targets, in part to support continued resource mobilisation efforts.

- **Deaths averted:** A target of 8-9 million future deaths averted with Gavi support. Given recalibration decisions, a US\$ 10 billion budget for Gavi 6.0, additional uncertainty in how countries use their vaccine budgets, and some downwards revisions to Vaccine Impact Modelling Consortium (VIMC) impact estimates, we expect a health impact loss of approximately 500,000 future deaths averted. This suggests the Alliance is likely to exceed 7.5 million future deaths averted. It could be challenging to reach the 8-9 million target unless Gavi is successful in fully funding the Gavi 6.0 replenishment ask of US\$ 11.9 billion.
- **Children immunised:** A target of 500 million children reached through routine immunisation with Gavi support. This indicator counts how many infant, 2-year-old and adolescent children receive at least one Gavi supported vaccine as opposed to multiple vaccines. This indicator is driven by guaranteed vaccine programmes and current forecasts suggest the Alliance will reach the target as it is less affected by funding shifts.
- **Economic benefits:** A target of > US\$ 100 billion in economic benefits unlocked through Gavi support. This indicator and target are computed from, and consistent with, the VIMC estimates of future deaths averted.

3.2 **Disability-adjusted live years (DALYs) averted:** The proposed target of 380-420 million future DALYs averted is consistent with the deaths averted target.

3.3 **Under-five mortality rate (U5MR):** A target of a 10% reduction is proposed.

3.4 **Zero-dose children:** As discussed at the PPC, Gavi will continue to support countries to achieve the IA2030 target of a 50% reduction in the number of zero-dose children between 2019 and 2030. Given the current context and recent trends, the Alliance will set a Gavi 6.0 accountability target reflecting its contribution towards the IA2030 goal, based on what may be achievable with Gavi resources. To accomplish this, a new indicator, “Additional zero-dose children reached” would be used, with a proposed target of 4-5 million children during Gavi 6.0. This level of ambition, which is commensurate with a range centred on a 10% reduction in the number of zero-dose children between 2025

and 2030 as originally proposed to the PPC, has been confirmed with the TWG, with further details in Annex B.

4. Targets for Gavi 6.0 strategic objective indicators

- 4.1 A summary of proposed targets for indicators measuring the four Strategic Goals (SG) is provided here, with dashboard and further rationale in Annex B.
- 4.2 **Strategy Goal 1:** For the indicator on vaccine prioritisation and optimisation (SG1a), a target of 90% of countries completing a robust portfolio prioritisation process as part of their applications for Gavi support is proposed. Under SG1b, following further consultation with the TWG at the request of the PPC, a target of 50% of 56 Gavi implementing countries reaching IPVc coverage of at least 80% is proposed. The Secretariat will report disaggregated data on 13 high-risk polio countries prioritised by the Global Polio Eradication Programme (GPEI). Beyond the approximately US\$ 1 billion that Gavi forecasts spending on IPV and hexavalent vaccines in Gavi 6.0, increasing IPVc coverage in these countries will depend on reaching missed communities with routine immunisation to reduce the number of zero-dose children and ensure those children are fully vaccinated. Nearly all 13 high-risk polio countries are in Gavi High Impact and Fragile & Conflict segments, underscoring Gavi's commitment to expanding routine coverage where it is most consequential for polio eradication. For breadth of protection, a target of +6 percentage points (pp) increase is proposed, noting current uncertainty in how countries will plan to use their vaccine budgets. For SG1c, a target of 25% of outbreaks with timely detection and response is proposed, with disaggregated reporting to understand steps of the outbreak response chain.
- 4.3 **Strategy Goal 2:** Many of the coverage indicators measuring SG2 are related to zero-dose ambition. The birth cohort is expected to rise by 5% by 2030 and health system reach is expected to keep pace and extend by improving full course of vaccination. Given this, the following targets are proposed: DTP3 coverage of +2pp, which assumes a 1pp reduction in DTP dropout; MCV1 coverage of +2pp, and MCV2 coverage of +2pp, noting only one country has yet to introduce MCV2. For geographic equity of DTP3 coverage, given data quality challenges, a qualitative target of increase from baseline is proposed. For HPV coverage, a target of a +10pp increase is proposed.
- 4.4 **Strategy Goal 3:** Proposed targets are 100% cofinancing fulfilment, 60% of preparatory and accelerated transition countries maintain or increase coverage of key vaccines (noting several countries with significant systems challenges moved into preparatory transition at the start of Gavi 6.0), and 15 vaccine introductions among catalytic phase countries.
- 4.5 **Strategy Goal 4:** Indicators emphasise supply security and affordability (see Gavi 6.0 Market Shaping Strategy, Doc 01d). SG4a has a proposed target of achieving acceptable supply security conditions in 17 out of 17 markets. Vaccine affordability is monitored through weighted average price (WAP) of

Gavi supported vaccines. Due to market sensitivity, the WAP target will remain confidential; WAP figures will be reported to the Board. Progress in regional manufacturing capacity in Africa is captured through a composite indicator, with the target of 16 advancements aligned to the AVMA MEL framework. Lastly, Gavi will track access to vaccines during outbreaks, epidemics, and pandemics through stockpile performance, targeting 100% of approved requests fulfilled.

5. Update on evidence prioritisation process

- 5.1 Focusing initially on priority use cases for 2026-2027, five main learning areas emerged through the centralised prioritisation process to address Gavi 6.0 evidence gaps with the US\$ 55 million Studies and Evaluations budget (Annex D): 1) early Gavi 6.0 shifts focused on Grant Management Reforms, including Country Vaccine Budgets; 2) optimising vaccine delivery strategies and platforms (including campaigns, integration and life course); 3) AVMA evaluability; 4) programme decisions and optimisation for specific vaccines, namely tuberculosis, measles-rubella, malaria, Mpox and diphtheria; and 5) use of Artificial Intelligence to enhance real-time assessment.
- 5.2 The learning questions for these five learning areas will be detailed, coordinated with other funder activities and prioritised by: a) importance for decision-making, b) urgency, and c) feasibility of generating timely evidence. Key Gavi 6.0 evaluations were already prioritised through this process. The Secretariat anticipates re-running the evidence prioritisation process for 2028-2030 in late 2027 and will manage emerging time-sensitive evidence needs through the Gavi Executive Leadership Team.

6 Update on Gavi 6.0 Evaluation Workplan and Evaluation Function Reform

- 6.1 Final Gavi 5.1 evaluations are underway with inception reports for The Big Catch-Up (BCU) and Private Sector and Innovation Strategy (PSI) currently under review and the Annual Evaluation Report (2025) published. The Gavi 6.0 Evaluation Workplan was shared with the Board in December 2025 and guidance provided by the Evaluation Advisory Committee (EAC) can be found in the EAC Chair's report to the Board (Doc 03).
- 6.2 The Gavi-Global Fund Task Force concluded in February 2026 that there are limited realisable efficiencies from enhanced evaluation collaboration at headquarters level and no substantial impact at country level. Gavi and the Global Fund will continue to share, learn and collaborate on evaluation workplans, sharing evidence, and strengthening methods and function approaches through a joint plan of activities (Annex E).
- 6.3 To inform changes through evaluation function reform, Gavi and the Global Fund shared learning on recent independent assessments of their evaluation functions and an analysis of the findings for issues identified across these assessments is provided (Annex F).

- 6.4 Revision of Gavi's Evaluation Policy is underway informed by guidance from the EAC and Governance Committee. The EAC recommended early, regular, and co-created engagement with the Secretariat, including consultation with the PPC. The Governance Committee welcomed enhanced engagement of the PPC on evaluations and the pathway towards a Board decision.

7. Next steps

- 7.1 The Gavi 6.0 Measurement Framework will inform the design of donor log frames for Gavi 6.0 and reporting will begin in 2027. The Secretariat is finalising the Gavi Leap Master Dashboard, in consultation with Alliance stakeholders, with initial reporting on the operational metrics in the second half of 2026.
- 7.2 The Secretariat will continue to work with the EAC and relevant governance bodies through 2026 to co-create the Evaluation Policy revision, clarify governance roles, and ensure the updated policy and approval pathway are aligned with broader governance reforms and the strategic needs of Gavi 6.0.
- 7.3 Learning questions for prioritised areas will be finalised and learning activities commissioned. Holistic overview and implementation status of Gavi learning activities will be brought to the PPC in October 2026 for information.

Annexes

Annex A: Implications and Anticipated impact

Annex B: Gavi 6.0 mission and strategy performance indicators and proposed targets

Annex C: Gavi Leap Master Dashboard indicators

Annex D: Early identified Gavi 6.0 learning areas (non-exhaustive)

Annex E: Gavi and Global Fund evaluation team proposed joint activities

Annex F: Mapping of key issues and response to Gavi and Global Fund assessments

Additional information available on BoardEffect

Appendix 1: Mission and strategy performance indicator reference sheets

Appendix 2: Evaluation Advisory Committee and Secretariat Response to the Evaluation Function Review (EFR)

Additional reference materials online

Gavi 6.0 Strategy: <https://www.gavi.org/our-alliance/strategy/phase-6-2026-2030>

Gavi 5.0 Measurement Framework:

<https://www.gavi.org/sites/default/files/programmes-impact/Measuring%20our%20performance/Gavi-50-Measurement-Framework.pdf>

Gavi 5.0 Learning System (i.e. MEL approach):

<https://www.gavi.org/sites/default/files/about/Strategy/LSS.pdf>

Annual Evaluation Report (2025):

<https://www.gavi.org/sites/default/files/evaluations/Gavi-Annual-Evaluation-Report-2025.pdf>